Trial Profile
A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Insulin peglispro (Primary) ; Insulin; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 26 Sep 2013 Results of an analysis in patients who underwent euglycaemic clamping (n=23) presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 05 Jul 2013 An Eli Lilly media release announces that an additional analysis exploring reduced mealtime insulin requirements for type 1 diabetes patients treated with insulin peglispro will be presented at the 73rd Annual ADA.
- 25 Jun 2013 Results of a sub-study presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.